CD30 Antibody (C-3): sc-46683
- CD30 Antibody (C-3) is a mouse monoclonal IgG1 κ CD30 antibody, cited in 3 publications, provided at 200 µg/ml
- raised against amino acids 416-595 mapping within a C-terminal cytoplasmic domain of CD30 of human origin
- CD30 Antibody (C-3) is recommended for detection of CD30 long and short form of mouse, rat and human origin by WB, IP, IF and ELISA
- Anti-CD30 Antibody (C-3) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for CD30 Antibody (C-3) for WB applications. These reagents are now offered in bundles with CD30 Antibody (C-3) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD30 Antibody (C-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD30 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD30 (C-3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD30, a member of the tumor necrosis factor receptor family, plays a crucial role in regulating immune responses and is primarily expressed on activated T and B lymphocytes, as well as neoplastic cells in Hodgkin′s lymphoma and other hematologic malignancies. CD30 structure, characterized by a cysteine-rich extracellular domain, is essential for ligand binding and subsequent signaling pathways that influence cell proliferation and survival. CD30 interacts with CD30L, which can have dual effects on cell growth; while promoting proliferation in Hodgkin′s cell lines, CD30L exhibits antiproliferative effects on large cell anaplastic lymphoma cell lines, highlighting the complexity of CD30 signaling in different cellular contexts. Anti-CD30 antibody (C-3) serves as a valuable tool for studying CD30 role in both normal immune function and pathological conditions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD30 Antibody (C-3) References:
- The role of CD30 in the pathogenesis of haematopoietic malignancies. | Al-Shamkhani, A. 2004. Curr Opin Pharmacol. 4: 355-9. PMID: 15251128
- Anti-CD30 Antibodies for Hodgkin lymphoma. | Foyil, KV. and Bartlett, NL. 2010. Curr Hematol Malig Rep. 5: 140-7. PMID: 20446121
- CD30: an important new target in hematologic malignancies. | Deutsch, YE., et al. 2011. Leuk Lymphoma. 52: 1641-54. PMID: 21619423
- Practical Management of CD30⁺ Lymphoproliferative Disorders. | Hughey, LC. 2015. Dermatol Clin. 33: 819-33. PMID: 26433852
- Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. | Pierce, JM. and Mehta, A. 2017. Expert Rev Hematol. 10: 29-37. PMID: 27927047
- The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response. | Marín, ND. and García, LF. 2017. Tuberculosis (Edinb). 102: 8-15. PMID: 28061955
- Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. | Xu, ML., et al. 2020. Am J Surg Pathol. 44: e1-e14. PMID: 31567279
- Prognostic Significance of CD30 in Transformed Mycosis Fungoides. | Travaglino, A., et al. 2021. Am J Clin Pathol. 156: 350-355. PMID: 33769436
- Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. | Jagadeesh, D., et al. 2022. Oncologist. 27: 864-873. PMID: 35948003
- Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas. | Tschernia, NP., et al. 2023. J Immunother Cancer. 11: PMID: 37527906
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD30 Antibody (C-3) | sc-46683 | 200 µg/ml | $322.00 | |||
CD30 Antibody (C-3): m-IgG Fc BP-HRP Bundle | sc-526725 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD30 Antibody (C-3): m-IgG1 BP-HRP Bundle | sc-532098 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD30 Antibody (C-3) AC | sc-46683 AC | 500 µg/ml, 25% agarose | $424.00 | |||
CD30 Antibody (C-3) HRP | sc-46683 HRP | 200 µg/ml | $322.00 | |||
CD30 Antibody (C-3) FITC | sc-46683 FITC | 200 µg/ml | $336.00 | |||
CD30 Antibody (C-3) PE | sc-46683 PE | 200 µg/ml | $349.00 | |||
CD30 Antibody (C-3) Alexa Fluor® 488 | sc-46683 AF488 | 200 µg/ml | $364.00 | |||
CD30 Antibody (C-3) Alexa Fluor® 546 | sc-46683 AF546 | 200 µg/ml | $364.00 | |||
CD30 Antibody (C-3) Alexa Fluor® 594 | sc-46683 AF594 | 200 µg/ml | $364.00 | |||
CD30 Antibody (C-3) Alexa Fluor® 647 | sc-46683 AF647 | 200 µg/ml | $364.00 | |||
CD30 Antibody (C-3) Alexa Fluor® 680 | sc-46683 AF680 | 200 µg/ml | $364.00 | |||
CD30 Antibody (C-3) Alexa Fluor® 790 | sc-46683 AF790 | 200 µg/ml | $364.00 |